Neuropathy – PharmaLive

Biogen’s Non-Opioid Pain Drug Shines in Small Fiber Neuropathy Study

Clinical Trials, Neurons, Non-opioid painkillers, R&D, Small fiber neuropathy (SFN), Tissue damage, Topline Data

Biogen reported positive topline results from the company’s Phase II CONVEY trial of vixotrigine for the treatment of small fiber neuropathy (SFN).

September 16, 2021/by BioSpace

MediciNova’s Ibudilast Reduces Retinal Thinning in MS Trial Subjects

Cancer Chemotherapy and Pharmacology, Chemotherapy-Induced Peripheral Neuropathy (CIPN), Clinical Data, Clinical Trials, Cytokines, Multiple Sclerosis, Multiple Sclerosis Journal, Peripheral Neuropathy, Progressive Multiple Sclerosis (MS), R&D, Small Molecules

MediciNova received positive Optical Coherence Tomography (OCT) results from the company’s SPRINT-MS Phase IIb trial of MN-166 (ibudilast) in multiple sclerosis subjects.

November 25, 2020/by BioSpace

Magnolia Neurosciences Launches with $31 Million

Alzheimer’s disease, Business, Neurological Conditions, Neuropathy, PARP Inhibitors, Series A

Magnolia Neurosciences, co-founded by Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center, launched with a $31 million Series A financing.

August 13, 2018/by BioSpace

Akcea and Ionis Announce EU Approval of Tegsedi

European Commission, FDA/Regulatory, Hereditary Transthyretin Amyloidosis (hATTR), Neuropathy, RNAi therapeutics

Akcea and Ionis’ Tegsedi (inotersen) received marketing authorization approval from the European Commission for treating stage 1 or stage 2 polyneuropathy in adults with hATTR.

July 11, 2018/by GlobeNewswire